Hanmi Pharmaceutical (KRX:128940) disposed of 11,180 common treasury shares to employees and officers on August 4 at the prior day's close of ₩345,500, for a total of ₩3.86 billion, transferred directly into recipients' brokerage accounts via Shinhan Investment. The filing's own reconciliation table flags the outcome as "inconsistent" with what the company originally scheduled: 10,402 shares planned versus 11,180 actually distributed, a gap the filing attributes to share-price movement and performance-evaluation results between the board's disposal decision and the actual settlement date. Separately, the filing notes Hanmi holds another 110,700 treasury shares acquired for a specific statutory purpose that are excluded from this table entirely.
| Symbol | Last Price |
|---|---|
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |
| 145020Hugel, Inc. | ₩244,000 +1.5% |
| 302440SK Bioscience Co., Ltd. | ₩37,900 +0.4% |
| 009420Hanall Biopharma Co., Ltd. | ₩54,700 +1.5% |